ClinicalTrials.gg
TerminatedNCT03010046Updated Aug 20, 2020

Single Dose Study of ANX005 in Healthy Volunteers

A Phase 1 interventional study of ANX005 and IVIg in Safety and Tolerability in Healthy Volunteers, sponsored by Annexon, Inc.. Terminated at 1 site in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-20.

Sponsored by Annexon, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
ANX005 well tolerated at doses studied; study discontinued and initiated in patient population

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a single-center, randomized, double-blind, placebo-controlled, ascending, single-infusion, sequential group study. Single, ascending doses will be administered to approximately 64 subjects, with an option for 1 additional multi-dose cohort in approximately 8 subjects. The primary objective is to evaluate the safety of ANX005 administered as an intravenous infusion as a single agent and in combination with intravenous immunoglobulin (IVIg). The optional multi-dose cohort will evaluate either additional subjects at the maximum tolerated dose or ANX005 administered as 2 infusions.

02

Conditions studied

  • Safety and Tolerability in Healthy Volunteers
03

In context

Lead sponsor

Annexon, Inc. is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and females 18 years and older
  • Females must be , surgically sterilized, or willing and able to use 2 methods of throughout the study and for 1 month after the final study visit
  • Willing and able to undergo vaccination if not vaccinated recently

Exclusion criteria

Exclusion Criteria:

  • History of any disease, meningitis, septicemia or pneumonia
  • History of hypercoagulable diseases, hyperviscosity, thrombosis, renal dysfunction or acute renal failure
  • Known genetic deficiencies of the complement cascade system
  • History of conditions whose symptoms and effects could alter protein catabolism or IgG utilization, e.g. protein-losing enteropathies or nephrotic syndrome
  • Body weight less than 50 kg or greater than 100 kg
  • or allergic reactions to any in the ANX005 drug product
  • (Cohorts 4b and 5b) Known selective IgA deficiency or presence of antibodies to IgA at screening
  • (Cohorts 4b and 5b) Prior reaction or hypersensitivity to blood products, including IVIg or any of the excipients in IVIg.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    ANX005 Monotherapy

    ANX005 intravenous infusion

    Drug: ANX005

  • Experimental
    ANX005 and IVIg Combination Therapy

    ANX005 intravenous infusion in combination with intravenous immunoglobulin (IVIg)

    Drug: ANX005 · Drug: IVIg

  • Placebo comparator
    Placebo

    Placebo intravenous infusion

    Drug: Placebos

Interventions

  • DrugANX005

    Single ascending dose intravenous infusion

  • DrugIVIg

    IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.

  • DrugPlacebos

    0.9% saline intravenous infusion

06

What researchers measure

Primary outcomes

  1. Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03

    Safety is assessed throughout the study. Day 43 is the last visit.

    Time frame: Day 43

Secondary outcomes

  1. Peak plasma concentration

    Time frame: Day 43

  2. Determine effective dose of ANX005

    Percent of subjects with a biologic response, defined as a reduction of serum CH50 percent change from baseline at 21 and 28 days after the first ANX005 infusion

    Time frame: Day 43

  3. Area under the plasma concentration versus time curve (AUC)

    Time frame: Day 43

  4. Terminal half-life

    Time frame: Day 43

Other outcomes

  1. Explore relationship of AUC with PD responses in serum

    Time frame: Day 43

  2. Explore relationship of AUC with PD responses in CSF

    Time frame: Day 43

  3. Explore relationship of half-life with PD responses in serum

    Time frame: Day 43

  4. Explore relationship of half-life with PD responses in CSF

    Time frame: Day 43

07

Study locations

1 site
  • Nucleus Network
    Melbourne, Victoria, Australia
08

References and documents

Publications

  • Lansita JA, Mease KM, Qiu H, Yednock T, Sankaranarayanan S, Kramer S. Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of Autoimmune and Neurodegenerative Diseases. Int J Toxicol. 2017 Nov/Dec;36(6):449-462. doi: 10.1177/1091581817740873. Epub 2017 Dec 4. PubMed 29202623 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Jun 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2016
First posted
Jan 4, 2017
Start
Dec 2016
Primary completionActual
Jun 2018
CompletionActual
Jun 2018
Last update
Aug 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03010046
Lead sponsor
Annexon, Inc.
Responsible party
Sponsor
First posted
Jan 4, 2017
Start date
Dec 2016
Primary completion
Jun 2018
Completion
Jun 2018
Last update
Aug 20, 2020

Study contacts

Sandy Calman, MD
study director · Annexon Medical Monitor
Jason Lickliter, MBBS PhD
principal investigator · Nucleus Network Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tanruprubart

Start the discussion